Company intelligence / Profile preview

Genovate Biotechnology

Hsinchu City, Hsinchu, Taiwangenovate-bio.com ↗

Ownership: Private
Employees: ~195
Development stage: Other

Overview

Genovate has a strong track record of developing new formulations of small molecule drugs, especially branded generics and controlled-release products. Its lead asset PMR (extended-release cilostazol) achieved primary endpoints in a pivotal bioequivalence trial supporting an upcoming NDA filing with the US FDA. The company also markets a broad portfolio of generic and specialty pharmaceuticals across multiple therapeutic areas.

Therapeutic areas: GastroenterologyEndocrinologyOncologyImmunologyCardiovascular
Modalities: Small moleculeBranded genericsControlled-release dosage forms
Industry: Biotech

Drug pipeline

2 assets

Nidadd

1 more asset in the full pipeline.

Request access →

Partnerships

NaviFUSUni PharmaSolenoDaiichi SankyoTSH BiopharmRoche

Beyond the preview

Go deeper on Genovate Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genovate Biotechnology.

Explore the full profile